Improvement of primary Sjögren’s syndrome salivary gland function by Xinfeng capsule and its effect on EGR1-STAT3 signaling pathway
Journal of Pharmacy and Pharmacology · 2025
DOI: 10.1093/jpp/rgae121 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Pharmacy and Pharmacology, 2025. Verfasst von Ling Zhu und 8 weiteren Autor:innen. Beteiligte Einrichtung: Experimental Center of Clinical Research, the First Affiliated Hospital of Anhui University of Chinese Medicine, Hefei 230031, Anhui, China. Hauptthemen laut MEDLINE: Sjogren's Syndrome, Salivary Glands, Drugs, Chinese Herbal, STAT3 Transcription Factor. Die Arbeit nennt 21 Literaturangaben. Gefördert von: National Natural Science Foundation of China, Research Preparation Plan Project of Anhui Province.
Abstract (Originalsprache)
Objectives
The study was aimed to investigate the effects of Xinfeng capsule (XFC) on tissue morphology, and gland function of the salivary gland (SG) in a primary Sjögren’s syndrome (pSS) mouse model.
Methods
An animal model of pSS was established by inducing SG protein in C57BL/6 mice. SG tissues were collected for tissue sequencing and subsequent experiments to detect the expression of cholinergic receptor muscarinic 3(M3R), early growth response factor 1 (EGR1) and target genes in the SG before and after XFC intervention, with in vitro validation.
Results
Downstream targets of the EGR1 gene were predicted and analyzed using data analysis. EGR1 showed high expression and was selected for subsequent experiments. Administration of XFC significantly increased saliva production (P < 0.001) and reduced the extent of lymphatic infiltration observed in SG. Furthermore, the expression of EGR1 was increased in the model group with statistical significance in contrast with the control group but decreased after administration of XFC (P < 0.05). Data analysis predicted the downstream target of EGR1 as signal transducer and activator of transcription 3 (STAT3), which was validated in SG tissues of mice (P < .05).
Conclusions
XFC demonstrated a significant improvement in the salivary secretion function of the SG in pSS mice. EGR1 can serve as a biomarker and therapeutic target for pSS.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Experimental Center of Clinical Research, the First Affiliated Hospital of Anhui University of Chinese Medicine, Hefei 230031, Anhui, China.
- Graduate School of Anhui Medical University, Hefei, 230031, Anhui, China.
- Otolaryngology-Head and Neck Surgery, the First Affiliated Hospital of Guangzhou University of Chinese Medicine, Guangzhou, 510405, China.
ORCID-Profile: Xingxing Huo
Förderung
- National Natural Science Foundation of China
- Research Preparation Plan Project of Anhui Province
Zitieren
APA
Zhu, L., Wang, B., Li, P., Cheng, G., Bu, S., Bian, S., Qiu, X., Liu, J., & Huo, X. (2025). Improvement of primary Sjögren’s syndrome salivary gland function by Xinfeng capsule and its effect on EGR1-STAT3 signaling pathway. Journal of Pharmacy and Pharmacology. https://doi.org/10.1093/jpp/rgae121
Vancouver
Zhu L, Wang B, Li P, Cheng G, Bu S, Bian S, et al. Improvement of primary Sjögren’s syndrome salivary gland function by Xinfeng capsule and its effect on EGR1-STAT3 signaling pathway. Journal of Pharmacy and Pharmacology. 2025. doi:10.1093/jpp/rgae121
BibTeX
@article{Zhu2025,
author = {Zhu, Ling and Wang, Beijia and Li, Pingping and Cheng, Gangli and Bu, Su and Bian, Sijie and Qiu, Xiaoting and Liu, Jian and Huo, Xingxing},
title = {Improvement of primary Sjögren’s syndrome salivary gland function by Xinfeng capsule and its effect on EGR1-STAT3 signaling pathway},
journal = {Journal of Pharmacy and Pharmacology},
year = {2025},
doi = {10.1093/jpp/rgae121}
}
EUVIMED